- Home
- CDT vs TOVX Comparison
CDT vs TOVX Comparison
Compare CDT & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDT
- TOVX
- Stock Information
- Founded
- CDT 2019
- TOVX 2001
- Country
- CDT United States
- TOVX United States
- Employees
- CDT N/A
- TOVX N/A
- Industry
- CDT Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- CDT Health Care
- TOVX Health Care
- Exchange
- CDT Nasdaq
- TOVX Nasdaq
- Market Cap
- CDT 4.6M
- TOVX 4.5M
- IPO Year
- CDT N/A
- TOVX 2006
- Fundamental
- Price
- CDT $1.18
- TOVX $0.40
- Analyst Decision
- CDT
- TOVX Hold
- Analyst Count
- CDT 0
- TOVX 1
- Target Price
- CDT N/A
- TOVX N/A
- AVG Volume (30 Days)
- CDT 160.1K
- TOVX 1.1M
- Earning Date
- CDT 08-14-2025
- TOVX 08-11-2025
- Dividend Yield
- CDT N/A
- TOVX N/A
- EPS Growth
- CDT N/A
- TOVX N/A
- EPS
- CDT N/A
- TOVX N/A
- Revenue
- CDT N/A
- TOVX N/A
- Revenue This Year
- CDT N/A
- TOVX N/A
- Revenue Next Year
- CDT N/A
- TOVX N/A
- P/E Ratio
- CDT N/A
- TOVX N/A
- Revenue Growth
- CDT N/A
- TOVX N/A
- 52 Week Low
- CDT $1.16
- TOVX $0.37
- 52 Week High
- CDT $274.80
- TOVX $4.97
- Technical
- Relative Strength Index (RSI)
- CDT 24.09
- TOVX 41.52
- Support Level
- CDT $1.47
- TOVX $0.39
- Resistance Level
- CDT $1.36
- TOVX $0.45
- Average True Range (ATR)
- CDT 0.11
- TOVX 0.03
- MACD
- CDT -0.01
- TOVX -0.00
- Stochastic Oscillator
- CDT 3.51
- TOVX 15.80
About CDT Conduit Pharmaceuticals Inc.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.